Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignacio Casanova

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Scientific Reports|March 28, 2026
Differential distribution of antiviral serology across multiple sclerosis phenotypes and its implications for disease pathogenesisDominguez-Mozo Maria Inmaculada, Stefano Ruberto, Carla Rodríguez-García, et al.
Annals of Clinical and Translational Neurology|March 4, 2025
Short-chain fatty acids in multiple sclerosis: Associated with disability, number of T2 lesions, and inflammatory profileMaria Inmaculada Dominguez-Mozo, Daniel López-Mecández, Luisa María Villar, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 2, 2026
Workplace difficulties in early-stage relapsing-remitting multiple sclerosis with low physical disabilityÁngel Pérez-Sempere, Elena García-Arcelay, Jacobo Caruncho, et al.
Journal of Personalized Medicine|April 27, 2026
Personalizing Relapsing-Remitting Multiple Sclerosis Monitoring: Patient Acceptance of Serum Neurofilament Light Chain and the Role of Disease KnowledgeÁngel Pérez-Sempere, Elena García-Arcelay, Jacobo Caruncho Pérez, et al.
International Journal of Molecular Sciences|September 28, 2024
Association of MicroRNA Expression and Serum Neurofilament Light Chain Levels with Clinical and Radiological Findings in Multiple SclerosisMaría Inmaculada Domínguez-Mozo, Ignacio Casanova, Enric Monreal, et al.
Journal of Neurology|May 1, 2020
Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish populationJulia Sabin, Sarai Urtiaga, Belen Pilo, et al.
CNS Drugs|November 23, 2020
Three-Year Effectiveness of Dimethyl Fumarate in Multiple Sclerosis: A Prospective Multicenter Real-World StudyBelen Pilo de la Fuente, Julia Sabín, Victoria Galán, et al.
European Journal of Neurology|June 21, 2021
Risk and outcomes of COVID-19 in patients with multiple sclerosisIrene Moreno-Torres, Virginia Meca Lallana, Lucienne Costa-Frossard, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Scientific Reports|March 28, 2026
Differential distribution of antiviral serology across multiple sclerosis phenotypes and its implications for disease pathogenesisDominguez-Mozo Maria Inmaculada, Stefano Ruberto, Carla Rodríguez-García, et al.
Annals of Clinical and Translational Neurology|March 4, 2025
Short-chain fatty acids in multiple sclerosis: Associated with disability, number of T2 lesions, and inflammatory profileMaria Inmaculada Dominguez-Mozo, Daniel López-Mecández, Luisa María Villar, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 2, 2026
Workplace difficulties in early-stage relapsing-remitting multiple sclerosis with low physical disabilityÁngel Pérez-Sempere, Elena García-Arcelay, Jacobo Caruncho, et al.
Journal of Personalized Medicine|April 27, 2026
Personalizing Relapsing-Remitting Multiple Sclerosis Monitoring: Patient Acceptance of Serum Neurofilament Light Chain and the Role of Disease KnowledgeÁngel Pérez-Sempere, Elena García-Arcelay, Jacobo Caruncho Pérez, et al.
International Journal of Molecular Sciences|September 28, 2024
Association of MicroRNA Expression and Serum Neurofilament Light Chain Levels with Clinical and Radiological Findings in Multiple SclerosisMaría Inmaculada Domínguez-Mozo, Ignacio Casanova, Enric Monreal, et al.
Journal of Neurology|May 1, 2020
Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish populationJulia Sabin, Sarai Urtiaga, Belen Pilo, et al.
CNS Drugs|November 23, 2020
Three-Year Effectiveness of Dimethyl Fumarate in Multiple Sclerosis: A Prospective Multicenter Real-World StudyBelen Pilo de la Fuente, Julia Sabín, Victoria Galán, et al.
European Journal of Neurology|June 21, 2021
Risk and outcomes of COVID-19 in patients with multiple sclerosisIrene Moreno-Torres, Virginia Meca Lallana, Lucienne Costa-Frossard, et al.
Pageof 4